Increase in incidence of infectious diseases is set to drive growth in the clinical microbiology market between 2017 and 2025 as clinical tests are required to diagnose these. As per CDC, un the year 2014, in the Unites States alone, approximately 10000 cases of tuberculosis, 33461 cases of Lyme Disease, 51455 cases of salmonella and 433 cases of meningococcal disease.
And, in 2017, the same country saw 1688780 cases of cancer reported, as per American Cancer Society. Other factor leading to growth in the market owing to need for clinical tests is the outbreaks of Zika, Ebola and other such pathogenic diseases.
Get Sample Copy of this Report @
Here it is important to note that lack of skilled professionals and a declining interest in medical laboratory training, in the United States and in certain developing nations is acting as a restraint in the market by automation in healthcare is soon set to compensate for the same.
The global clinical microbiology market is consolidated and key players that dominate the market landscape include bioMerieux S.A.; Cepheid Inc.; Danaher Corporation; and Bruker Corporation. Others that have also successfully made their mark on the market playfield include Becton Dickinson & Company; Hologic Inc.; Roche Diagnostics; and Alere Inc.
Most of the players have a sharp focus on integrated technology with their products, with a particular interest in automation. And, thus it comes as no surprise that players are investing in innovation in a big way, thereby, intensifying competition in the global clinical microbiology market.
Check Table of Contents of this Report @ https://www.tmrresearch.com/sample/sample?flag=T&rep_id=1199
Over the forecast period, North America will account for a major share of revenue in the market. The reasons are obvious – well developed healthcare sector and high adoption of advanced diagnostic techniques. Besides, prominent market players flanking the market landscape are also contributing positively to the growth of the region over the forecast period.